What is PRRT? Peptide Receptor Radionuclide Therapy (PRRT) is a molecular targeted therapy used to treat the NET tumors such as gastroenteropancreatic NET tumors (Carcinoid/stomach, intestines, and pancreas), small cell carcinoma of the lung, and other tissues of the neuroendocrine system, such as pheochromocytoma (a rare tumor on the adrenal glands). The goals of PRRT are to treat symptoms, to slow or stop the progression of NET tumors, and improve overall quality of life. Candidates for PRRT are patients who have advanced NET tumors (mainly grades 1 and 2), are not candidates for surgery, and patients who have not had symptoms respond to other treatments.
So, how does it work? Tumor cells have peptide receptors on located on the outside. In NET tumors, this receptor is called the somatostatin receptor. A lab-created somatostatin protein (octreotide) is binded with a small amount of lutetium (a radioactive particle). When injected into the bloodstream, this mixture binds to the tumor via the somatostatin receptor and treats the tumor from the inside, delivering a high dose of radiation to the tumor.
*Please remember to discuss all medical options with a NET specialist. This is so important in finding the correct treatment plan for you.*
Here are some sources to learn more about PRRT: